{"id":584481,"date":"2026-06-10T00:00:00","date_gmt":"2026-06-10T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0014-2026-biopharma-ischemic-stroke-landscape-forecast-disease-landscape-forecast-g7\/"},"modified":"2026-06-10T00:00:00","modified_gmt":"2026-06-10T00:00:00","slug":"dlsfcg0014-2026-biopharma-ischemic-stroke-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0014-2026-biopharma-ischemic-stroke-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Ischemic Stroke &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>Acute ischemic stroke (<abbr title=\"acute ischemic stroke\">AIS<\/abbr>) affects millions of individuals across G7 countries, according to Clarivate Epidemiology\u2019s tracked lifetime and 12-month prevalent cohorts. As a time-critical emergency, <abbr title=\"acute ischemic stroke\">AIS<\/abbr> necessitates rapid intervention to preserve salvageable brain tissue. The standard of care includes <abbr title=\"intravenous\">IV<\/abbr> thrombolysis within 4.5 hours and mechanical thrombectomy for eligible large-vessel occlusions. Roche \/ Genentech\u2019s tenecteplase has expanded reperfusion options, offering a longer half-life and single-bolus administration compared with alteplase. Despite this advance, further innovation in the management of <abbr title=\"acute ischemic stroke\">AIS<\/abbr> is sorely needed to bring neuroprotective\/restorative\/reparative\u00a0and other new therapies to <abbr title=\"acute ischemic stroke\">AIS<\/abbr> patients to optimize their functional recovery. However, few strategies in this arena have achieved clear clinical proof-of-concept, and trial failures have been the historical norm. Nonetheless, the <abbr title=\"acute ischemic stroke\">AIS<\/abbr> pipeline is large, active, and diverse regarding mechanisms of action, and the field is focused on advancing trial design.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How has the adoption of tenecteplase impacted <abbr title=\"acute ischemic stroke\">AIS<\/abbr> treatment in the United States and Europe?<\/li>\n<li>Which pharmacotherapies designed to be complementary to thrombolysis and\/or thrombectomy to improve <abbr title=\"acute ischemic stroke\">AIS<\/abbr> outcomes hold the most promise according to key opinion leaders? What minimum levels of efficacy, safety, ease of use, and cost-effectiveness would be required for these therapies to meaningfully impact <abbr title=\"acute ischemic stroke\">AIS<\/abbr> treatment practice?\n<div><\/div>\n<\/li>\n<li>What factors might limit the uptake of new neuroprotective or reparative agents?<\/li>\n<li>Is late-window thrombolysis a promising strategy to expand the addressable <abbr title=\"acute ischemic stroke\">AIS<\/abbr> market?<\/li>\n<li>What are the key unmet needs and opportunities in <abbr title=\"acute ischemic stroke\">AIS<\/abbr>, and can branded innovation credibly create value?<\/li>\n<\/ul>\n<p><strong>Geography:<\/strong> United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan<\/p>\n<p><strong>Primary research: <\/strong>Country-specific interviews with 14 thought-leading neurologists; survey data collected for this and other Clarivate research<\/p>\n<p><strong>Epidemiology: <\/strong>Total, diagnosed, and drug-treated ischemic stroke events<\/p>\n<p><strong>Drug treatments:<\/strong> Coverage of key current and late-phase emerging therapies<\/p>\n<p><strong>Forecast: <\/strong>10-year, annualized, drug-level sales and patient share of key <abbr title=\"acute ischemic stroke\">AIS<\/abbr> therapies through 2034, segmented by brands\/generics.<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"BulletListStyle1 SCXW245248806 BCX0 round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-584481","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ischemic-stroke","biopharma-therapy-areas-neurology","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/584481","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=584481"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}